Quarterly snapshots from biopharma companies with marketed products, including: United Therapeutics, Ultragenyx.

With a Nov. 6 FDA adcom meeting on Biogen Inc.'s Alzheimer's candidate, aducanumab, creeping ever closer, the candidate's prospects stole the show in its third-quarter earnings report, even outshining attention to the cloud of generics raining on the company's years-long Tecfidera (dimethyl fumarate) parade. FDA acceptance for aducanumab's BLA lines the candidate up for a priority review and regulatory action by March 7, the company said. Furthermore, global progress remains underway, with an EU marketing application now made and one in Japan on deck.

Quarterly snapshots from biopharma companies with marketed products, including: Flexion, Genmab.

Quarterly snapshots from biopharma companies with marketed products, including: Supernus.

Quarterly snapshots from biopharma companies with marketed products, including: Zai Lab.

Quarterly snapshots from biopharma companies with marketed products, including: Redhill, Zai.

Quarterly snapshots from biopharma companies with marketed products, including: Adamas, Astellas, Beigene, Dynavax, Exelixis, Fibrogen, Incyte, Morphosys, Novartis.

Quarterly snapshots from biopharma companies with marketed products, including: Catalyst, Rockwell.

Quarterly snapshots from biopharma companies with marketed products, including: Amicus, Intercept, Radius.

Quarterly snapshots from biopharma companies with marketed products, including: Adamas, Amag, Beigene, Clovis, Coherus, Exelixis, Dynavax, Fibrogen, GW, Ocular, Puma.